AdvantiGen's novel patented reactivation technology and proprietary high-throughput hybridoma platform allows our team to produce significantly more antigen specific clones than standard fusion procedures. Furthermore, these technologies allow us to generate antibodies with higher affinities than what is identified by traditional hybridoma technologies.
Our team has extensive experience developing polyclonal, monoclonal and recombinant antibodies. We can design the antigen or the target. Utilizing our technology will increase the successful identification of your desired antibody and accelerate your development process.